Search - tctmd.com

Displaying 681 - 700 of 879

Sort: Relevancy | Date

Presentation TCT 2013

TCT-18. Clinical and Procedural Predictors and Consequences of Stent Thrombosis Following Drug-eluting Stents for Acute Coronary Syndromes: Results From the ADAPT-DES Study

Presenter: Ankit Garg

October 29, 2013

Presentation TCT 2013

TCT-13. Final Five Year Results From The All-comer COMPARE Trial: A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents

Presenter: Peter Smits

October 29, 2013

Presentation TCT 2013

Comparison of Polymer-Free BioFreedom™ Stents with Durable Polymer Taxus Liberté™ Stents: 4-Year Results from the BioFreedom First-In-Man Trial

Presenter: 208788|Ricardo Costa

October 29, 2013

Presentation TCT 2013

Use Of 4 French Systems For Treating Fem-Pop Lesions: Advantages And Disadvantages: Lessons From The 4EVER Trial Using Astron Pulsar Stents And No Closure Devices

Presenter: Koen Keirse

October 29, 2013

Presentation TCT 2013

TCT-50. Angiographic Predictor of 2-Year Stent Thrombosis in Patients Receiving Drug-eluting Stents: Insights from the ADAPT-DES Study

Presenter: Philippe Généreux

October 29, 2013

Presentation TCT 2013

TCT-16. Incidence, mechanisms and outcome of longitudinal stent deformation (LSD) associated with Element, Resolute, Biomatrix and Xience stents: angiographic and case-by-case...

Presenter: Samer Arnous

October 29, 2013

Presentation TCT 2013

TCT-12. Short Versus Long-Term Clinical Outcomes In A Randomised Comparison Of Zotarolimus- and Sirolimus-Eluting Coronary Stents

Presenter: Michael Maeng

October 29, 2013

Presentation TCT 2013

SORT-OUT VI: A Prospective, Randomized, All-Comers Trial of Biodegradable Polymer-Coated Biolimus-Eluting Stents vs. Biocompatible Polymer-Coated Zotarolimus-Eluting Coronary...

Presenter: Bent Raungaard

October 29, 2013

Presentation TCT 2013

Biodegradable-Polymer Drug-Eluting Stents versus Bare Metal Stents versus Durable-Polymer Drug-Eluting Stents : A Systematic Review and Bayesian Approach Network Meta-Analysis

Presenter: Si-Hyuck Kang

October 29, 2013

News Conference News TCT 2013

State of the Stent: PCI Future Intact Despite Costs, Sociopolitical Factors

October 29, 2013

Presentation TCT 2013

PROTECT: Four-Year Results from a Prospective, Randomized Trial of Sirolimus-Eluting Stents and Zotarolimus-Eluting Stents

Presenter: Laura Mauri

October 28, 2013

Presentation TCT 2013

Everolimus-eluting Stents in Left Main Disease: The ULMD Florence PCI Registry (with Angiographic Follow-up)

Presenter: David Antoniucci

October 28, 2013

Presentation TCT 2013

The Case for Dedicated Bifurcation Stents; Device and Regulatory Landscape; and Anticipation of the Pivotal Tryton Results

Presenter: Martin Leon

October 28, 2013

Presentation TCT 2013

Synthesis of the ISAR Clinical Trials Comparing Different Stents in Different Settings

Presenter: Adnan Kastrati

October 28, 2013

Presentation TCT 2013

SYNTAX COST-EFFECTIVENESS: Final Five-Year Results from a Prospective, Randomized Trial of Paclitaxel-Eluting Stents vs. CABG in Patients with Triple Vessel and Left Main Corona...

Presenter: David Cohen

October 28, 2013

Presentation TCT 2013

Stents and Pharmacotherapy in STEMI: Anticipating HORIZONS-AMI II

Presenter: Gregg Stone

October 28, 2013

Presentation TCT 2013

Everolimus-eluting Stents in Left Main Disease: Precombat II 3 Year Results

Presenter: Young-Hak Kim

October 28, 2013

Presentation TCT 2013

Dedicated Bifurcation Stents for the Left Main: Experience with Axxess, Tryton and Others

Presenter: Eulogio Garcia

October 28, 2013

Presentation TCT 2013

Contra Position: Dedicated Bifurcation Stents are a Historical Cconcept and are No Longer Needed!

Presenter: Bernard Chevalier

October 28, 2013

Presentation TCT 2013

Case #2: A Complex Bifurcation: Dedicated Stent, Planned 2 Stents or Provisional Stent strategy?

Presenter: Gregory Pavlides

October 28, 2013

Advertisement

TCT-18. Clinical and Procedural Predictors and Consequences of Stent Thrombosis Following Drug-eluting Stents for Acute Coronary Syndromes: Results From the ADAPT-DES Study

TCT-13. Final Five Year Results From The All-comer COMPARE Trial: A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents

Comparison of Polymer-Free BioFreedom™ Stents with Durable Polymer Taxus Liberté™ Stents: 4-Year Results from the BioFreedom First-In-Man Trial

Use Of 4 French Systems For Treating Fem-Pop Lesions: Advantages And Disadvantages: Lessons From The 4EVER Trial Using Astron Pulsar Stents And No Closure Devices

TCT-50. Angiographic Predictor of 2-Year Stent Thrombosis in Patients Receiving Drug-eluting Stents: Insights from the ADAPT-DES Study

TCT-16. Incidence, mechanisms and outcome of longitudinal stent deformation (LSD) associated with Element, Resolute, Biomatrix and Xience stents: angiographic and case-by-case...

TCT-12. Short Versus Long-Term Clinical Outcomes In A Randomised Comparison Of Zotarolimus- and Sirolimus-Eluting Coronary Stents

SORT-OUT VI: A Prospective, Randomized, All-Comers Trial of Biodegradable Polymer-Coated Biolimus-Eluting Stents vs. Biocompatible Polymer-Coated Zotarolimus-Eluting Coronary...

Biodegradable-Polymer Drug-Eluting Stents versus Bare Metal Stents versus Durable-Polymer Drug-Eluting Stents : A Systematic Review and Bayesian Approach Network Meta-Analysis

State of the Stent: PCI Future Intact Despite Costs, Sociopolitical Factors

PROTECT: Four-Year Results from a Prospective, Randomized Trial of Sirolimus-Eluting Stents and Zotarolimus-Eluting Stents

Everolimus-eluting Stents in Left Main Disease: The ULMD Florence PCI Registry (with Angiographic Follow-up)

The Case for Dedicated Bifurcation Stents; Device and Regulatory Landscape; and Anticipation of the Pivotal Tryton Results

Synthesis of the ISAR Clinical Trials Comparing Different Stents in Different Settings

SYNTAX COST-EFFECTIVENESS: Final Five-Year Results from a Prospective, Randomized Trial of Paclitaxel-Eluting Stents vs. CABG in Patients with Triple Vessel and Left Main Corona...

Stents and Pharmacotherapy in STEMI: Anticipating HORIZONS-AMI II

Everolimus-eluting Stents in Left Main Disease: Precombat II 3 Year Results

Dedicated Bifurcation Stents for the Left Main: Experience with Axxess, Tryton and Others

Contra Position: Dedicated Bifurcation Stents are a Historical Cconcept and are No Longer Needed!

Case #2: A Complex Bifurcation: Dedicated Stent, Planned 2 Stents or Provisional Stent strategy?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content